Portal de Periódicos da CAPES

Upper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: the 2010 multidisciplinary French consensus - part 1

2011; Wiley; Volume: 10; Issue: 1 Linguagem: Inglês

10.1111/j.1473-2165.2010.00544.x

1473-2165

Hervé Raspaldo, Martine Baspeyras, Philippe Bellity, Jean‐Marie Dallara, V. Gassia, François‐Rene Niforos, Lakhdar Belhaouari,

Facial Nerve Paralysis Treatment and Research

Background Onabotulinumtoxin A (onabotulinum) has been used for 7 years in the treatment of the aging face. A survey was conducted to identify current practices in France. Objective To develop consensual practice recommendations for treating the aging upper- and mid-face with onabotulinum. Methods and Materials Fifty-seven participants reviewed practices and techniques for each identified upper- and mid-face treatment indication. From data gathered during six regional conferences and from a questionnaire, consensual recommendations were developed. Results General considerations, key treatment rules, injection specifics (dose, site, and techniques), associated procedures/treatments, and follow-up were defined for each indication, i.e., glabellar, horizontal forehead, crow's feet and bunny lines, lower eyelid rhytides, and eyebrow repositioning and reshaping. For the consensus participants, current onabotulinum use is a global, both preventive and corrective treatment. In France, judicious lowest effective dose, treatment of multiple sites and adjunctive treatment modalities, such as fillers and peels, lead to satisfactory results for clinicians and patients with a youthful, harmonious, animated and natural looking face. Conclusions Years of experience using onabotulinum result in sophisticated treatment approaches, more specific targeted injections, and a better understanding of facial aging, leading to satisfying therapeutic results for both patients and clinicians.